Ritlecitinib

Cat. No.: 0225LY-1361

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Ritlecitinib is an orally bioavailable, selective JAK3 inhibitor with an IC50 of 33.1 nM that does not interfere with the activities of JAK1 or JAK2.

Synonym: PF-06651600; 1792180-81-4; 2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one; 1-((2S,5R)-2-methyl-5-((7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one; 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)piperidin-1-yl)prop-2-en-1-one; 1-[(2S,5R)-2-methyl-5-({7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)piperidin-1-yl]prop-2-en-1-one

CAS No.: 1792180-81-4

Compound CID: 118115473

Formula: C₁₅H₁₉N₅

Formula Weight: 285.34